Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Financial News

Tetragenetics gets JDRF investment

May 2, 2017 7:07 PM UTC

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Cambridge, Mass.), the company said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes.

Tetragenetics said that by targeting ion channels involved in the regulation of T cell activation, including KCNA3 and potassium channel KCa3.1 (KCNN4), it seeks to halt autoimmune cascades that lead to disease. It uses its TetraExpress platform to produce large amounts of correctly folded, functional ion channels, which it says allows it to overcome a bottleneck in creating ion channel-targeting mAbs...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

JDRF

TetraGenetics Inc.